Corteva's genetically modified Enlist platform has had wins over Bayer in recent years in gaining approval for its GMO seeds to be imported into China, which should boost Enlist's market share.

Bank of America Securities analyst Steve Byrne maintained a Sell rating on DuPont de Nemours (DD – Research Report) today and set a price ...

With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and ...

Mizuho Securities analyst John Roberts CFA has maintained their bullish stance on DD stock, giving a Buy rating on October 24. John Roberts ...

S&P Dow Jones Indices will replace chemical and plastics maker Dow Inc. on the Dow Jones Industrial Average list with Sherwin ...

Barclays analyst Michael Leithead raised the firm’s price target on DuPont (DD) to $85 from $84 and keeps an Underweight rating on the shares. The ...

In a tough fundraising space, cell therapy biotechs pursuing autoimmune indications review staffing to ensure the right ...

A 79-year-old man who was killed after he rode his electric bike into the path of a pickup truck Saturday has been identified by police as William Blatt. Delaware State Police said part of their ...

DuPont de Nemours raised its full-year profit forecast after topping third-quarter estimates on Tuesday, as the industrial ...

DuPont de Nemours has a better P/E ratio of 104.94 than the aggregate P/E ratio of 47.08 of the Chemicals industry. Ideally, ...

Shares of materials conglomerate DuPont rose after the company reported better-than-expected earnings. There were some encouraging signs of business improvement.DuPont on Tuesday announced adjusted ...

Good morning and thank you for joining us for DuPont’s third quarter 2024 financial results conference call ... and we expect to be able to announce board members of each company, along with key ...